<DOC>
	<DOCNO>NCT02652052</DOCNO>
	<brief_summary>The investigator hope find proof principle concept pilot study investigator design clinical trial base result explanatory hypothesis .</brief_summary>
	<brief_title>Hematopoietic Stem Cell Transplant Survivors Study ( HTSS Study )</brief_title>
	<detailed_description>HSCT survivor increase risk premature age . No one evaluate biologic marker premature age senescence HSCT survivor correlation clinical outcome , lifestyle , nutrition . The investigator evaluate age-related change HSCT survivor , specify measure premature age , employ therapeutic opportunity base target senescent cell conduct first in-human pilot study senolytic drug ( HSCT survivor utilize combination senolytics ) .</detailed_description>
	<mesh_term>Quercetin</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>Inclusion Criteria Allogeneic HSCT patient survive ≥ 1 year postHSCT Diagnosis malignant nonmalignant condition HSCT indication HSCT survivor receive type conditioning chemo/radiotherapy HSCT Ability provide write verbal informed consent Age ≥ 18 year Adequate blood count i.e . platelet &gt; 50,000 per microliter ; HB &gt; 9/dL , ANC &gt; 1000 per microliter Exclusion Criteria HSCT survivor human immunodeficiency virus ( HIV ) infection HSCT survivor active hepatitis B C HSCT survivor TKI either Philadelphia chromosome positive cancer GVHD treatment indication ( e.g. , imatinib GIST , sorafenib FLT3+ AML etc ) HSCT survivor posttransplant maintenance chemotherapy Posttransplant relapse cancer Active progressive CHRONIC chronic overlap GVHD ( per NIH chronic GVHD criterion ) Presence uncontrolled psychiatric disorder Patient unable give inform consent Extremely poor overall prognosis ( &lt; 6 month deem primary transplant physician ) HSCT survivor confirm drug addiction HSCT survivor active coronary artery disease ( CAD ) [ include angina ] active congestive heart failure ( CHF ) International HSCT survivor loss followup would concern deem primary transplant physician Known hypersensitivity allergy dasatinib , quercetin Presence uncontrolled lupus Presence uncontrolled pleural/pericardial effusion ascites Presence active new cancer ( solid hematologic ) except nonmelanoma skin cancer Presence progeroid syndrome family Invasive fungal viral infection respond appropriate antifungal antiviral therapy . Creatinine clearance &lt; 60 mL/min/1.73 m2 base CockcroftGault Inability tolerate oral medication Total bilirubin &gt; 2x upper limit normal ( unless deem due Gilbert 's syndrome ) ; AST/ALT &gt; 2.5x ULN Active progressive ACUTE graftversushost disease Active progressive OVERLAP graftversushost disease Patients take medication sensitive substrate substrate narrow therapeutic range CYP3A4 , CYP2C8 , CYP2C9 , CYP2D6 strong inhibitor inducer CYP3A4 ( e.g . cyclosporine , tacrolimus sirolimus ) . If antifungal absolutely necessary infectious disease perspective , allow level therapeutic . Levels check baseline also day +4 post intervention . Patients take H2antagonists proton pump inhibitor . Patients therapeutic dos anticoagulant ( e.g . warfarin , heparin , low molecular weight heparin , factor Xa inhibitor etc ) . On antiplatelet agent ( e.g . full dose aspirin , clopidogrel etc. ) . Baby aspirin absolutely necessary cardiac perspective allow . On quinolone antibiotic therapy treatment prevention infection . QTc &gt; 450 msec . Common drug well know prolong QTc include azithromycin , citalopram , escitalopram , fluconazole , pentamidine . Baselines EKG obtain patient QTc &gt; 450 msec , exclude trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>